Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (4): 108-113.doi: 10.6040/j.issn.1671-7554.0.2020.1670

Previous Articles     Next Articles

Clinical value of targeted multiparameter MRI and transrectal ultrasonography fusion prostate biopsy for the detection of PI-RADS≥3 prostate cancer

SUN Dingqi, FU Qiang, ZHANG Hui, LIU Shuai, DIAO Tongxiang, CAO Qingwei, ZHANG Keqin   

  1. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
  • Published:2021-04-30

PDF (PC)

188

Abstract: Objective To evaluate the clinical value of multiparameter magnetic resonance imaging(mpMRI)and transrectal ultrasonography(TRUS)fusion prostate biopsy for the detection of prostate cancer(PCa)and clinical significant prostate cancer(csPCa). Methods A total of 161 patients treated during Sep. 2018 and Jun. 2020 with prostate imaging reporting and data system(PI-RADS)≥3 were enrolled in this study. The patients were randomly assigned to undergo either systematic prostate biopsy(systematic group)or targeted mpMRI/TRUS fusion prostate biopsy + systematic prostate biopsy(combined group). The clinical data and pathological results of biopsies were analyzed. Results The detection rate of PCa by targeted mpMRI/TRUS fusion prostate biopsy was higher than that of systematic prostate biopsy, but there was no significantly difference(χ2=0.627,P=0.429). There were 40 cases in the combined group and 22 in the systematic group diagnosed as csPCa, respectively. The detection rate of csPCa was much higher in the combined group(χ2=8.139, P=0.004). When Gleason score>6, targeted mpMRI/TRUS fusion prostate biopsy had significantly higher detection rate than systematic biopsy(P=0.010). Conclusion In patients with PI-RADS≥3 prostate cancer, targeted mpMRI/TRUS fusion prostate biopsy has higher detection rates of PCa and csPCa than systematic prostate biopsy, but it still misses some cases. Combination of targeted mpMRI/TRUS fusion prostate biopsy and systematic prostate biopsy can improve the detection rate of all prostate cancers, especially csPCa.

Key words: Prostate cancer, Targeted biopsy, Multiparameter magnetic resonance imaging, Transrectal ultrasonography fusion, Prostate imaging reporting and data system

CLC Number: 

  • R737.25
[1] Zhai Z, Zheng Y, Li N, et al. Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017[J]. Cancer, 2020, 126(9): 1969-1978.
[2] Pang C, Guan Y, Li H, et al. Urologic cancer in China[J]. Jpn J ClinOncol, 2016, 46(6): 497-501.
[3] DAgostino D, Romagnoli D, Giampaoli M, et al. “In-Bore” MRI-guided prostate biopsy for prostate cancer diagnosis: results from 140 consecutive patients[J]. CurrUrol, 2020, 14(1): 22-31.
[4] Stabile A, DellOglio P, Gandaglia G, et al. Not all Multiparametric magnetic resonance imaging-targeted biopsies are equal: the impact of the type of approach and operator expertise on the detection of clinically significant prostate cancer[J]. Eur Urol Oncol, 2018, 1(2): 120-128.
[5] Tang Y, Liu Z, Tang L, et al. Significance of MRI/Transrectal ultrasound fusion three-dimensional model-guided, targeted biopsy based on transrectal ultrasound-guided systematic biopsy in prostate cancer detection: a systematic review and meta-analysis[J]. Urol Int, 2018, 100(1): 57-65.
[6] Ahmed HU, El-ShaterBosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS): a paired validating confirmatory study[J]. Lancet, 2017, 389(10071): 815-822.
[7] Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer[J]. JAMA, 2015, 313(4): 390-397.
[8] Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients(MRI-FIRST): a prospective, multicentre, paired diagnostic study[J]. Lancet Oncol, 2019, 20(1): 100-109.
[9] Guo G, Xu Y, Zhang X. TRUS-guided transperineal prostate 12+X core biopsy with template for the diagnosis of prostate cancer[J]. Oncol Lett, 2017, 13(6): 4863-4867.
[10] Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting[J]. EurUrol, 2011, 59(4): 477-494.
[11] Xiang J, Yan H, Li J, et al. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis[J]. World J Surg Oncol, 2019, 17(1): 31. doi: 10.1186/s12957-019-1573-0.
[12] Huang H, Wang W, Lin T, et al. Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy[J]. BMC Urol, 2016, 16(1): 68.
[13] Omer A, Lamb AD. Optimizing prostate biopsy techniques[J].Curr Opin Urol, 2019, 29(6): 578-586.
[14] Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis[J]. N Engl J Med, 2020, 382(10): 917-928.
[15] Elkhoury FF, Felker ER, Kwan L, et al. Comparison of targeted vs. systematic prostate biopsy in men who are biopsy naive: the prospective assessment of image registration in the diagnosis of prostate cancer(PAIREDCAP)study[J]. JAMA Surg, 2019, 154(9): 811-818.
[16] Drost FH, Osses DF, Nieboer D, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer[J]. Cochrane Database Syst Rev, 2019, 4(4): CD012663.
[17] 白志杰,王新胜,马洪顺,等. mpMRI与超声融合导航技术在前列腺靶向穿刺的临床研究[J].首都医科大学学报,2020,41(4): 631-635. BAI Zhijie, WANG Xinshen, MA Hongshun, et al. Clinical study of multiparameter magnetic resonance imaging and ultrasound fusion navigation technology in prostate targeted puncture[J]. Journal of Capital Medical University, 2020, 41(4): 631-635.
[18] 侯健全,席启林,浦金贤,等.经直肠超声与磁共振融合成像靶向穿刺技术在首次诊断性前列腺穿刺中的应用[J].中华泌尿外科杂志,2017,38(6): 469-472. HOU Jianquan, XI Qilin, PU Jinxian, et al. The value of transrectal ultrasound and magnetic resonance imaging fusion targeted prostate biopsy in biopsy-native men[J]. Chinese Journal of Urology, 2017, 38(6): 469-472.
[19] Stabile A, Giganti F, Rosenkrantz AB, et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions[J]. Nat Rev Urol, 2020, 17(1):41-61.
[20] Drudi FM, Cantisani V, Angelini F, et al. Multiparametric MRI Versus multiparametric US in the detection of prostate cancer[J]. Anticancer Res, 2019, 39(6):3101-3110.
[21] Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis[J]. Eur Urol, 2015, 68(3): 438-450.
[22] Baco E, Rud E, Eri LM, et al. A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy[J]. Eur Urol, 2016, 69(1): 149-156.
[23] Porpiglia F, Manfredi M, Mele F, et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naïve patients with suspected prostate cancer[J]. Eur Urol, 2017, 72(2): 282-288.
[24] Nassiri N, Beeder L, Nazemi A, et al. Step-by-step: fusion-guided prostate biopsy in the diagnosis and surveillance of prostate cancer[J]. Int Braz J Urol, 2019, 45(6):1277-1278.
[25] Elwenspoek M, Sheppard AL, McInnes M, et al. Comparison of multiparametric magnetic resonance imaging and targeted biopsy with systematic biopsy alone for the diagnosis of prostate cancer: a systematic review and meta-analysis[J]. JAMA Netw Open, 2019, 2(8): e198427.
[26] Filson CP, Natarajan S, Margolis DJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies[J]. Cancer, 2016, 122(6): 884-892.
[1] SUN Haoyu, JIANG Xin, CHEN Shouzhen, QU Sifeng, SHI Benkang. Multiparametric magnetic resonance imaging combined with prostate health index in the diagnosis of prostate cancer in 142 patients within PSA grey zone [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 46-50.
[2] XU Zhen, DIAO Tongxiang, ZANG Zhenjie, SHAO Dingchang, ZHANG Qi, SUN Dingqi, FU Qiang. Value of isoform［-2］proprostate-specific antigen and its derivatives in the diagnosis of prostate cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 51-56.
[3] Benkang SHI,Shouzhen CHEN,Sifeng QU,Yong WANG,Lei LIU. Research progress and clinical characteristics of clinical rapidly progressing prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 110-116.
[4] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[5] ZHU Gang, ZHANG Kai. Chinese prostate cancer screening: current situation and challenges [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 11-15.
[6] LÜ Jiaju, HU Jialin, DING Sentai. Advances in focal therapy for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 1-5.
[7] WANG Haitao. Development of precision medicine in the treatment of castration-resistant prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 30-35.
[8] HAN Bangmin, JING Yifeng. Clinical management of oligometastatic prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 26-29.
[9] YAO Xudong. Strategy and efficacy of surgical treatment in locally advanced prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 21-25.
[10] SU Hengchuan, ZHU Yao, DAI Bo, LIU Chang, HU Silong, YE Dingwei. Significance of 99mTc-PSMA SPECT/CT guided salvage lymph node dissection for prostate cancer patients with biochemical recurrence [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 36-40.
[11] ZHOU Fangjian, HUANG Hua, LI Yonghong. Focal cryoablation for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 6-10.
[12] MAO Shaowei, LU Guoliang, LI Liang, XIA Qinghua. Valproic acid augments the anti-tumor potential of metformin in PC-3 cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 48-53.
[13] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[14] ZHAI Hongyun, ZHANG Denglu, WANG Guangjie, KONG Feng, CHENG Guanghui, ZHAO Shengtian. Effects of factors secreted by mouse embryonic stem cells on prostate cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 8-12.
[15] DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1. Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 33-36.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] LYU Longfei, LI Lin, LI Shuhai, QI Lei, LU Ming, CHENG Chuanle, TIAN Hui. Application of laparoscopic fine needle catheter jejunostomy in minimally invasive McKeown resection of esophageal cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 77 -81 .
[2] SHAO Haigang, WANG Xuan, WANG Qing. Anatomy of the root canal system of mandibular first premolar in population of Shandong Province[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 85 -89 .
[3] JIANG Bao-dong,MA Xiang-xing,WANG Qing,WANG Qian,FENG Xiao-yuan,LI Ke,YU Fu-hua. Imaging parameters of multislice spiral CT venography in cerebral veins[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(11): 1084 -1086 .
[4] TANG Fang1,2, ZHANG Yingqian3, WANG Zhiqiang4, KANG Dianmin4,
WANG Jiezhen1, XUE Fuzhong1. A 2D minimal spanning tree model of the spatial structures of natural focal disease[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 106 -110 .
[5] LI Yu-liang,WANG Yong-zheng,WANG Xiao-hua,ZHANG Fu-jun,ZHU Li-dong,ZHANG Wang-ming,LI Zheng,LI Zhen-jia,ZHANG Kai-xian. I implantation combined with Gemcitabine in the treatment of advanced pancreatic cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(4): 393 -396 .
[6] ZHU Xiaoli1, GUO Shuling1, SU Lei1, FENG Yuxin2, YUAN Fangshu1. Extraction of total proteins from demodex and qualification of their molecular weights[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(5): 58 -62 .
[7] WANG Xiaoju1，　WANG Mingming2，　XU Wansu2,　ZHAO Shengmei3，CUI Sunan2，　LI Xiaoying2，　LIU Chunhua1
. Expression of peripheral blood lymphocyte ubiquitin mRNA in chronic HBV infection with active inflammation and its clinical significance[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(02): 58 -61 .
[8] MA Li-Xin, LI Gang, SU Yu-Hang, ZHANG Cai, ZHANG Jian. Expression of NKG2D on NK cells in intracranial tumors[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(5): 88 -91 .
[9] LIU Hai-Chun, ZHANG Jian-Feng, CHEN Yuan-zhen. Bone collagen and biomechanical propertyies in the femur of osteoporosis rats[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(5): 42 -45 .
[10] FENG Fuli1, WEI Shuzhen2, ZHANG Yonghuan3, LI Li1, CHEN Rong1, LIRuifeng1. Relationship between high mortality and altered expression of Klotho in insulin resistance rats[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(6): 5 -8 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd